Drug intelligence / Profile preview

CBT004

Development stage: Preclinical
Lead developer: Cloudbreak Pharma
Modality: Antibody-Based Therapeutics
Administration: Ophthalmic, Topical

Overview

CBT004 is a lead preclinical candidate, a CD83-targeting antibody developed for the prophylaxis and treatment of graft-versus-host disease (GVHD) and transplant rejection. The technology originated from research at the Australian Cooperative Research Centre for Biomarker Translation (CRC-BT), in collaboration with the University of Queensland and the University of California San Francisco, based on discoveries by Professor Derek Hart's group at the University of Sydney. TransBio licensed this technology to DendroCyte BioTech, which is advancing the drug into clinical development.

Targets

CD83 (CD83 antigen)

Beyond the preview

Go deeper on CBT004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBT004.

Explore the full profile